Composite outcomes: Weighting component events according to severity assisted interpretation but reduced statistical power

Journal of Clinical Epidemiology

Volumn 63, Issue 10, 2010, Pages 1156-1158

  Sampson, Uchechukwu K A ^a   Metcalfe, Chris ^c   Pfeffer, Marc A ^b   Solomon, Scott D ^b   Zou, Kelly H ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Binary outcomes; Composite score; Disease burden; Illness episodes; Statistical power; Treatment effect; Weighted endpoints

Indexed keywords

CAPTOPRIL; PLACEBO;

ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CONTROLLED STUDY; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; BIOASSAY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; METHODOLOGY; OUTCOME ASSESSMENT; RISK; STATISTICS;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX;

EID: 78349288498     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2010.01.019     Document Type: Article

References (13)

1. Metcalfe C, Thompson SG, Cowie MR, Sharples LD. The use of hospital admission data as a measure of outcome in clinical studies of heart failure. Eur Heart J 2003;24:105-12.
2. Neaton JD, Wentworth DN, Rhame F, Hogan C, Abrams DI, Deyton L. Considerations in choice of a clinical endpoint for AIDS clinical trials. Stat Med 1994;13:2107-25.
3. Massel D. Composite confusion. JAm Coll Cardiol 2004;43:1926-7.
4. Neaton JD, Gray G, Zuckerman BD, Konstam MA. Key issues in end point selection for heart failure trials: composite end points. J Card Fail 2005;11:567-75.
5. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
6. Pfeffer MA, Greaves SC, Arnold JM, Glynn RJ, LaMotte FS, Lee RT, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The Healing and Early Afterload Reducing Therapy Trial. Circulation 1997;95:2643-51.
7. Kirkwood BR, Sterne JAC. Essential medical statistics. 2nd ed. Oxford, UK: Blackwell; 2003. pp. 350-3.
8. Cannon CP. Clinical perspectives on the use of composite endpoints. Control Clin Trials 1997;18:517-29.
9. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003;289:2554-9.
10. Ferreira-Gonzalez I, Permanyer-Miralda G, Busse JW, Bryant DM, Montori VM, Alonso-Coello P, et al. Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. J Clin Epidemiol 2007;60:651-7.
11. Freemantle N, Calvert M. Weighing the pros and cons for composite outcomes in clinical trials. J Clin Epidemiol 2007;60:658-9.
12. Montori VM, Permanyer-Miralda G, Ferreira-Gonzalez I, Busse JW, Pacheco-Huergo V, Bryant D, et al. Validity of composite end points in clinical trials. BMJ 2005;330:594-6.
13. Lubsen J, Kirwan BA. Combined endpoints: can we use them? Stat Med 2002;21:2959-70.